Literature DB >> 32469698

Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease.

Elena Popugaeva1, Daria Chernyuk1, Ilya Bezprozvanny1,2.   

Abstract

Despite decades of research and effort, there is still no effective disease-modifying treatment for Alzheimer's Disease (AD). Most of the recent AD clinical trials were targeting amyloid pathway, but all these trials failed. Although amyloid pathology is a hallmark and defining feature of AD, targeting the amyloid pathway has been very challenging due to low efficacy and serious side effects. Alternative approaches or mechanisms for our understanding of the major cause of memory loss in AD need to be considered as potential therapeutic targets. Increasing studies suggest that Ca2+ dysregulation in AD plays an important role in AD pathology and is associated with other AD abnormalities, such as excessive inflammation, increased ROS, impaired autophagy, neurodegeneration, synapse, and cognitive dysfunction. Ca2+ dysregulation in cytosolic space, Endoplasmic Reticulum (ER) and mitochondria have been reported in the context of various AD models. Drugs or strategies, to correct the Ca2+ dysregulation in AD, have been demonstrated to be promising as an approach for the treatment of AD in preclinical models. This review will discuss the mechanisms of Ca2+ dysregulation in AD and associated pathology and discuss potential approaches or strategies to develop novel drugs for the treatment of AD by targeting Ca2+ dysregulation. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Alzheimer's disease; calcium hypothesis; cytosolic space; endoplasmic reticulum (ER); nSOCE; therapeutic agents.

Year:  2020        PMID: 32469698      PMCID: PMC8210816          DOI: 10.2174/1567205017666200528162046

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  157 in total

1.  Graded activation of CRAC channel by binding of different numbers of STIM1 to Orai1 subunits.

Authors:  Zhengzheng Li; Lin Liu; Yongqiang Deng; Wei Ji; Wen Du; Pingyong Xu; Liangyi Chen; Tao Xu
Journal:  Cell Res       Date:  2010-09-14       Impact factor: 25.617

2.  Effect of amyloid beta on capacitive calcium entry in neural 2a cells.

Authors:  Ying Niu; Zuqi Su; Chang Zhao; Bo Song; Xiufang Zhang; Nanming Zhao; Xun Shen; Yandao Gong
Journal:  Brain Res Bull       Date:  2008-11-08       Impact factor: 4.077

Review 3.  Calcium channelopathies and Alzheimer's disease: insight into therapeutic success and failures.

Authors:  Shreaya Chakroborty; Grace E Stutzmann
Journal:  Eur J Pharmacol       Date:  2013-12-06       Impact factor: 4.432

4.  Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons.

Authors:  S L Chan; M Mayne; C P Holden; J D Geiger; M P Mattson
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

5.  Familial Alzheimer's disease mutations in presenilins: effects on endoplasmic reticulum calcium homeostasis and correlation with clinical phenotypes.

Authors:  Omar Nelson; Charlene Supnet; Huarui Liu; Ilya Bezprozvanny
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 6.  The role of apolipoprotein E in Alzheimer's disease.

Authors:  Jungsu Kim; Jacob M Basak; David M Holtzman
Journal:  Neuron       Date:  2009-08-13       Impact factor: 17.173

7.  Presenilin-dependent expression of STIM proteins and dysregulation of capacitative Ca2+ entry in familial Alzheimer's disease.

Authors:  Lukasz Bojarski; Pawel Pomorski; Aleksandra Szybinska; Mirosław Drab; Anna Skibinska-Kijek; Joanna Gruszczynska-Biegala; Jacek Kuznicki
Journal:  Biochim Biophys Acta       Date:  2008-12-06

8.  Calcium signaling and neurodegeneration.

Authors:  I B Bezprozvanny
Journal:  Acta Naturae       Date:  2010-04       Impact factor: 1.845

9.  SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production.

Authors:  Kim N Green; Angelo Demuro; Yama Akbari; Brian D Hitt; Ian F Smith; Ian Parker; Frank M LaFerla
Journal:  J Cell Biol       Date:  2008-06-30       Impact factor: 10.539

Review 10.  Clinical trials of new drugs for Alzheimer disease.

Authors:  Li-Kai Huang; Shu-Ping Chao; Chaur-Jong Hu
Journal:  J Biomed Sci       Date:  2020-01-06       Impact factor: 8.410

View more
  5 in total

1.  New Approaches to Develop Drug Treatment for Alzheimer's Disease: Targeting Calcium Dysregulation.

Authors:  Huafeng Wei
Journal:  Curr Alzheimer Res       Date:  2020       Impact factor: 3.498

Review 2.  Cav3 T-Type Voltage-Gated Ca2+ Channels and the Amyloidogenic Environment: Pathophysiology and Implications on Pharmacotherapy and Pharmacovigilance.

Authors:  Anna Papazoglou; Muhammad Imran Arshaad; Christina Henseler; Johanna Daubner; Karl Broich; Jürgen Hescheler; Dan Ehninger; Britta Haenisch; Marco Weiergräber
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

Review 3.  Dysregulated Ca2+ Homeostasis as a Central Theme in Neurodegeneration: Lessons from Alzheimer's Disease and Wolfram Syndrome.

Authors:  Manon Callens; Jens Loncke; Geert Bultynck
Journal:  Cells       Date:  2022-06-18       Impact factor: 7.666

Review 4.  Potential Drug Candidates to Treat TRPC6 Channel Deficiencies in the Pathophysiology of Alzheimer's Disease and Brain Ischemia.

Authors:  Veronika Prikhodko; Daria Chernyuk; Yurii Sysoev; Nikita Zernov; Sergey Okovityi; Elena Popugaeva
Journal:  Cells       Date:  2020-10-24       Impact factor: 6.600

Review 5.  Computer-Based Drug Design of Positive Modulators of Store-Operated Calcium Channels to Prevent Synaptic Dysfunction in Alzheimer's Disease.

Authors:  Lernik Hunanyan; Viktor Ghamaryan; Ani Makichyan; Elena Popugaeva
Journal:  Int J Mol Sci       Date:  2021-12-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.